REG - Immupharma PLC - Result of WRAP Retail Offer and TVR

ImmuPharmaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260323:nRSW6124Xa&default-theme=true

RNS Number : 6124X  Immupharma PLC  23 March 2026

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND,
CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER
JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE
A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION
21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN
APPROVED BY WINTERFLOOD SECURITIES LIMITED WHICH IS AUTHORISED AND REGULATED
BY THE FINANCIAL CONDUCT AUTHORITY (FRN 141455).

 

 

23 March 2026

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Result of WRAP Retail Offer and TVR

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, further to its Fundraising announcement published on 17 March 2026 at
7:00 a.m. (the "Fundraising RNS") and the WRAP Retail Offer announcement
published on 17 March 2026 at 7:01 a.m. (the "WRAP RNS"), announces the
result of the WRAP Retail Offer and provide an update on the Fundraising.

 

The Company has raised gross proceeds of £468,746.82 from the WRAP Retail
Offer at the Issue Price and will, accordingly, issue 7,812,447 WRAP Retail
Offer Shares pursuant to the WRAP Retail Offer.

 

Accordingly, in total, the Subscription and the WRAP Retail Offer have raised
gross proceeds of approximately £6.468m for the Company, via the issue of the
100,000,000 Subscription Shares and the 7,812,447 WRAP Retail Offer Shares all
at the Issue Price.

 

Additionally, as detailed in the Fundraising RNS, the Company is also issuing
12,000,000 Value Payment Shares and 1,375,000 Fee Shares at the Issue Price.

 

The allotment of the Subscription Shares, WRAP Retail Offer Shares, Value
Payment Shares and Fee Shares requires prior approval by the Company's
Shareholders at the General Meeting which is scheduled for 11.00 a.m. on 7
April 2026. Contingent on approval of the Resolutions at the General Meeting
Admission is expected to take place at 8.00 a.m. on 8 April 2026.

 

Admission and Total Voting Rights

 

Application will be made for a total of 121,187,447 new Ordinary Shares to be
admitted to trading on AIM. It is expected that, contingent on approval of the
Resolutions at the General Meeting, Admission of the 100,000,000 Subscription
Shares, 12,000,000 Value Payment Shares, 7,812,447 WRAP Retail Offer Shares
and 1,375,000 Fee Shares will become effective and dealings in those shares
will commence at 8:00 a.m. on 8 April 2026.

 

Upon admission of the Subscription Shares, the Value Payment Shares, the WRAP
Retail Offer Shares and the Fee Shares, the Company's issued ordinary share
capital will comprise 623,911,379 Ordinary Shares with one voting right each.
The Company does not hold any Ordinary Shares in treasury. This figure may be
used by Shareholders in the Company as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

All new Ordinary Shares, including the Subscription Shares, the Value Payment
Shares, the WRAP Retail Offer Shares and the Fee Shares, will be issued free
of all liens, charges and encumbrances and will, from respective admissions,
rank pari passu in all respects with the Company's existing Ordinary Shares.

 

 

Terms used but not defined in this announcement have the same meaning as set
out in the Fundraising RNS and / or WRAP RNS.

 

For further information, please contact:

 

 ImmuPharma PLC (www.immupharma.co.uk)       +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations    + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)     +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)    44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                   +44 (0) 1483 413500

 Nick Emerson

 Winterflood Retail Access Platform          WRAP@winterflood.com

 Sophia Bechev, Kaitlan Billings             +44(0) 20 3100 0214

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

This announcement should be read in its entirety. In particular, the
information in the "Important Notices" section of the announcement should be
read and understood.

 

Important Notices

 

The content of this announcement has been prepared by and is the sole
responsibility of the Company.

 

The release, publication or distribution of this announcement may be
restricted by law in certain jurisdictions and persons into whose possession
any document or other information referred to herein comes should inform
themselves about and observe any such restriction. Any failure to comply with
these restrictions may constitute a violation of the securities laws of any
such jurisdiction.

 

This announcement and the information contained herein is not for release,
publication or distribution, directly or indirectly, in whole or in part, in
or into or from the United States (including its territories and possessions,
any state of the United States and the District of Columbia (the "United
States" or "US")), Australia, Canada, New Zealand, Japan, the Republic of
South Africa, any member state of the EEA or any other jurisdiction where to
do so might constitute a violation of the relevant laws or regulations of such
jurisdiction. This announcement does not constitute an offer to sell or issue
or a solicitation of an offer to buy or subscribe for Ordinary Shares in any
such jurisdiction.

 

This announcement is not for publication or distribution, directly or
indirectly, in or into the United States of America.  This announcement is
not an offer of securities for sale into the United States.  The securities
referred to herein have not been and will not be registered under the US
Securities Act, and may not be offered or sold in the United States, except
pursuant to an applicable exemption from registration.  No public offering of
securities is being made in the United States.

 

WRAP is a proprietary technology platform owned and operated by Winterflood
Securities Ltd (registered address at Riverbank House, 2 Swan Lane, London
EC4R 3GA; FRN 141455). Winterflood Securities Ltd ("Winterflood") is
authorised and regulated in the United Kingdom by the Financial Conduct
Authority, is acting exclusively for the Company and for no-one else and will
not regard any other person (whether or not a recipient of this announcement)
as its client in relation to the WRAP Retail Offer and will not be responsible
to anyone other than the Company for providing the protections afforded to its
clients, nor for providing advice in connection with the WRAP Retail Offer,
Admission and the other arrangements referred to in this announcement.

 

The value of Ordinary Shares and the income from them is not guaranteed and
can fall as well as rise due to stock market movements. When you sell your
investment, you may get back less than you originally invested. Figures refer
to past performance and past performance is not a reliable indicator of future
results. Returns may increase or decrease as a result of currency
fluctuations.

 

Certain statements in this announcement may constitute forward-looking
statements which are based on the Company's expectations, intentions and
projections regarding its future performance, anticipated events or trends and
other matters that are not historical facts. These forward-looking statements,
which may use words such as "aim", "anticipate", "believe", "intend",
"estimate", "expect" and words of similar meaning, include all matters that
are not historical facts. These forward-looking statements involve risks,
assumptions and uncertainties that could cause the actual results of
operations, financial condition, liquidity and dividend policy and the
development of the industries in which the Company's businesses operate to
differ materially from the impression created by the forward-looking
statements. These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties and other factors that could
cause actual results to differ materially from those expressed or implied by
such forward-looking statements. Given those risks and uncertainties,
prospective investors are cautioned not to place undue reliance on
forward-looking statements.

 

These forward-looking statements speak only as at the date of this
announcement and cannot be relied upon as a guide to future performance. The
Company and Winterflood expressly disclaim any obligation or undertaking to
update or revise any forward-looking statements contained herein to reflect
actual results or any change in the assumptions, conditions or circumstances
on which any such statements are based unless required to do so by the
Financial Conduct Authority, the London Stock Exchange or applicable law.

 

The information in this announcement is for background purposes only and does
not purport to be full or complete. None of Winterflood or any of its
affiliates, accepts any responsibility or liability whatsoever for, or makes
any representation or warranty, express or implied, as to this announcement,
including the truth, accuracy or completeness of the information in this
announcement (or whether any information has been omitted from the
announcement) or any other information relating to the Company or associated
companies, whether written, oral or in a visual or electronic form, and
howsoever transmitted or made available or for any loss howsoever arising from
any use of the announcement or its contents or otherwise arising in connection
therewith. Winterflood and its affiliates, accordingly disclaim all and any
liability whether arising in tort, contract or otherwise which they might
otherwise be found to have in respect of this announcement or its contents or
otherwise arising in connection therewith.

 

Any indication in this announcement of the price at which the Ordinary Shares
have been bought or sold in the past cannot be relied upon as a guide to
future performance. Persons needing advice should consult an independent
financial adviser. No statement in this announcement is intended to be a
profit forecast and no statement in this announcement should be interpreted to
mean that earnings or target dividend per share of the Company for the current
or future financial years would necessarily match or exceed the historical
published earnings or dividends per share of the Company.

 

Neither the content of the Company's website (or any other website) nor the
content of any website accessible from hyperlinks on the Company's website (or
any other website) is incorporated into or forms part of this announcement.
The WRAP Retail Offer Shares to be issued or sold pursuant to the WRAP Retail
Offer will not be admitted to trading on any stock exchange other than the
London Stock Exchange.

 

It is further noted that the WRAP Retail Offer was only open to investors in
the United Kingdom who fall within Article 43 of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes
an existing member of the Company).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIEAPDAAFFKEFA



            Copyright 2019 Regulatory News Service, all rights reserved